Latest Posts

27

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

German VC firm invests in Data as a Service startup Innoplexus

Innoplexus, a Germany- and India-based Data as a Service (DaaS) startup, has closed an undisclosed sum in pre-Series A funding from HCS, a Germany-based Venture VC firm.

With the capital, the startup plans to file more patent applications, further develop its trademark platform iPlexus, and invest in marketing.

Started in 2011, Innoplexus helps life sciences companies generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of a drug. Its DaaS engine with real-time data and insights, along with an ecosystem of Continuous Analytics as a Service (CAaaS) applications, helps enterprises make better data-driven decisions.

Headquartered in Germany, with over 100 employees working from Pune, Innoplexus services large global pharma and life sciences companies. It helps companies move to continuous decision making by generating insights from structured and unstructured private and public data.

The company’s iPlexus platform helps life science firms to generate intelligence and insights across pre-clinical, clinical, regulatory and commercial stages of a drug across therapeutic areas and indications. It also helps researchers get quick, crisp and summarised snapshots of the current landscape in any given context through an intuitive semantic search, helping them make informed and data-backed decisions.

Dr. Gunjan Bhardwaj, Co-founder and CEO of Innoplexus, said, “We envision to fundamentally transform the DaaS landscape for life sciences by leveraging machine learning and artificial intelligence to generate insights from the public as well as enterprise data.”

Gaurav Tripathi, Co-founder and India CEO, said, “We are working in cutting-edge technology areas of Information Retrieval, Network Analysis, Computer Vision and Ontologies and are one of the rare startups with a strong focus on creating proprietary Intellectual Property.”

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…